Noven Pharmaceuticals Inc. Completes Phase 3 Clinical Program for Investigational Non-Hormonal Therapy for Menopausal Vasomotor Symptoms

MIAMI & NEW YORK--(BUSINESS WIRE)--Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced that it has completed the Phase 3 clinical development program evaluating low-dose mesylate salt of paroxetine (LDMP) for the treatment of vasomotor symptoms (VMS) associated with menopause (hot flashes). The Phase 3 clinical program was comprised of two studies involving an aggregate of 1,180 subjects from more than 130 centers across the U.S.

Back to news